Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8780629rdf:typepubmed:Citationlld:pubmed
pubmed-article:8780629lifeskim:mentionsumls-concept:C0006142lld:lifeskim
pubmed-article:8780629lifeskim:mentionsumls-concept:C1516213lld:lifeskim
pubmed-article:8780629lifeskim:mentionsumls-concept:C0031809lld:lifeskim
pubmed-article:8780629lifeskim:mentionsumls-concept:C0741343lld:lifeskim
pubmed-article:8780629lifeskim:mentionsumls-concept:C0032743lld:lifeskim
pubmed-article:8780629lifeskim:mentionsumls-concept:C1527121lld:lifeskim
pubmed-article:8780629lifeskim:mentionsumls-concept:C0302995lld:lifeskim
pubmed-article:8780629pubmed:issue17lld:pubmed
pubmed-article:8780629pubmed:dateCreated1996-10-4lld:pubmed
pubmed-article:8780629pubmed:abstractTextThe presence of metastatic tumor cells in the axillary lymph nodes is an important factor when deciding whether or not to treat breast cancer patients with adjuvant therapy. Positron emission tomography (PET) imaging with the radiolabeled glucose analogue 2-(fluorine-18)-fluoro-2-deoxy-D-glucose (F-18 FDG) has been used to visualize primary breast tumors as well as bone and soft-tissue metastases.lld:pubmed
pubmed-article:8780629pubmed:languageenglld:pubmed
pubmed-article:8780629pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8780629pubmed:citationSubsetIMlld:pubmed
pubmed-article:8780629pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8780629pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8780629pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8780629pubmed:statusMEDLINElld:pubmed
pubmed-article:8780629pubmed:monthSeplld:pubmed
pubmed-article:8780629pubmed:issn0027-8874lld:pubmed
pubmed-article:8780629pubmed:authorpubmed-author:WeberWWlld:pubmed
pubmed-article:8780629pubmed:authorpubmed-author:RömerWWlld:pubmed
pubmed-article:8780629pubmed:authorpubmed-author:HespRRlld:pubmed
pubmed-article:8780629pubmed:authorpubmed-author:DornPPlld:pubmed
pubmed-article:8780629pubmed:authorpubmed-author:GraeffHHlld:pubmed
pubmed-article:8780629pubmed:authorpubmed-author:SchwaigerMMlld:pubmed
pubmed-article:8780629pubmed:authorpubmed-author:ZieglerSSlld:pubmed
pubmed-article:8780629pubmed:authorpubmed-author:NathrathWWlld:pubmed
pubmed-article:8780629pubmed:authorpubmed-author:JänickeFFlld:pubmed
pubmed-article:8780629pubmed:authorpubmed-author:AvrilNNlld:pubmed
pubmed-article:8780629pubmed:issnTypePrintlld:pubmed
pubmed-article:8780629pubmed:day4lld:pubmed
pubmed-article:8780629pubmed:volume88lld:pubmed
pubmed-article:8780629pubmed:ownerNLMlld:pubmed
pubmed-article:8780629pubmed:authorsCompleteYlld:pubmed
pubmed-article:8780629pubmed:pagination1204-9lld:pubmed
pubmed-article:8780629pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:8780629pubmed:meshHeadingpubmed-meshheading:8780629-...lld:pubmed
pubmed-article:8780629pubmed:meshHeadingpubmed-meshheading:8780629-...lld:pubmed
pubmed-article:8780629pubmed:meshHeadingpubmed-meshheading:8780629-...lld:pubmed
pubmed-article:8780629pubmed:meshHeadingpubmed-meshheading:8780629-...lld:pubmed
pubmed-article:8780629pubmed:meshHeadingpubmed-meshheading:8780629-...lld:pubmed
pubmed-article:8780629pubmed:meshHeadingpubmed-meshheading:8780629-...lld:pubmed
pubmed-article:8780629pubmed:meshHeadingpubmed-meshheading:8780629-...lld:pubmed
pubmed-article:8780629pubmed:meshHeadingpubmed-meshheading:8780629-...lld:pubmed
pubmed-article:8780629pubmed:meshHeadingpubmed-meshheading:8780629-...lld:pubmed
pubmed-article:8780629pubmed:meshHeadingpubmed-meshheading:8780629-...lld:pubmed
pubmed-article:8780629pubmed:meshHeadingpubmed-meshheading:8780629-...lld:pubmed
pubmed-article:8780629pubmed:meshHeadingpubmed-meshheading:8780629-...lld:pubmed
pubmed-article:8780629pubmed:meshHeadingpubmed-meshheading:8780629-...lld:pubmed
pubmed-article:8780629pubmed:meshHeadingpubmed-meshheading:8780629-...lld:pubmed
pubmed-article:8780629pubmed:year1996lld:pubmed
pubmed-article:8780629pubmed:articleTitleAssessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.lld:pubmed
pubmed-article:8780629pubmed:affiliationDepartment of Nuclear Medicine, Technische Universität München, Federal Republic of Germany.lld:pubmed
pubmed-article:8780629pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8780629lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8780629lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8780629lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8780629lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8780629lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8780629lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8780629lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8780629lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8780629lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8780629lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8780629lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8780629lld:pubmed